Finch Therapeutics Q4 2021 net loss $19.1M; PRISM4 trial on hold, CFO retiring

Finch Therapeutics Group, Inc.

2023-Q1 EPS reported -$0.52 revenue$354,000

Net loss of $19.1M in Q4 2021 ($13.1M in Q4 2020); full year loss $58.2M ($39.3M in 2020).
Cash and equivalents $133.5M at Dec 31, 2021; expected to fund operations into mid-2023.
PRISM4 Phase 3 trial of CP101 in recurrent C. difficile remains on clinical hold; at least one quarter delay.
Paused development of CP101 for chronic HBV to focus on CDI and autism programs.
CFO Greg Perry to retire April 30, 2022; COO Marc Blaustein to serve as principal financial officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.